These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 10708054)

  • 1. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.
    Mulligan K; Grunfeld C; Tai VW; Algren H; Pang M; Chernoff DN; Lo JC; Schambelan M
    J Acquir Immune Defic Syndr; 2000 Jan; 23(1):35-43. PubMed ID: 10708054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
    Shikuma CM; Yang Y; Glesby MJ; Meyer WA; Tashima KT; Ribaudo HJ; Webb N; Bastow B; Kuritzkes DR; Gulick RM
    J Acquir Immune Defic Syndr; 2007 Apr; 44(5):540-50. PubMed ID: 17245230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use.
    Hadigan C; Corcoran C; Stanley T; Piecuch S; Klibanski A; Grinspoon S
    J Clin Endocrinol Metab; 2000 Jan; 85(1):35-41. PubMed ID: 10634360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative effects of insulin resistance and protease inhibitor treatment on lipid and lipoprotein metabolism in HIV-infected patients.
    Beatty G; Chu J; Kulkarni K; Lipshutz G; Khalili M; Abbasi F; Stansell J; Reaven GM
    HIV Clin Trials; 2004; 5(6):383-91. PubMed ID: 15682351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.
    Martínez E; Conget I; Lozano L; Casamitjana R; Gatell JM
    AIDS; 1999 May; 13(7):805-10. PubMed ID: 10357379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy.
    Shlay JC; Bartsch G; Peng G; Wang J; Grunfeld C; Gibert CL; Visnegarwala F; Raghavan SS; Xiang Y; Farrough M; Perry HE; Kotler D; El-Sadr WM
    J Acquir Immune Defic Syndr; 2007 Apr; 44(5):506-17. PubMed ID: 17325603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
    Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T
    Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
    Tebas P; Yarasheski K; Henry K; Claxton S; Kane E; Bordenave B; Klebert M; Powderly WG
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):589-94. PubMed ID: 15242534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors.
    Melvin AJ; Lennon S; Mohan KM; Purnell JQ
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1117-23. PubMed ID: 11522181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.
    Petit JM; Duong M; Duvillard L; Piroth L; Grappin M; Verges B; Chavanet P; Brun JM; Portier H
    Horm Metab Res; 2000 Sep; 32(9):367-72. PubMed ID: 11014386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus.
    Ergun-Longmire B; Lin-Su K; Dunn AM; Chan L; Ham K; Sison C; Stavola J; Vogiatzi MG
    Endocr Pract; 2006; 12(5):514-21. PubMed ID: 17014060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.
    Behrens G; Dejam A; Schmidt H; Balks HJ; Brabant G; Körner T; Stoll M; Schmidt RE
    AIDS; 1999 Jul; 13(10):F63-70. PubMed ID: 10416516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.
    Hatano H; Miller KD; Yoder CP; Yanovski JA; Sebring NG; Jones EC; Davey RT
    AIDS; 2000 Sep; 14(13):1935-42. PubMed ID: 10997397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
    Bickel M; Rickerts V; Stephan C; Jacobi V; Rottmann C; Dauer B; Carlebach A; Thalhammer A; Miller V; Staszweski S
    HIV Med; 2005 May; 6(3):179-84. PubMed ID: 15876284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.
    Busti AJ; Bedimo R; Margolis DM; Hardin DS
    J Investig Med; 2008 Feb; 56(2):539-44. PubMed ID: 18317438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.
    Tomazic J; Karner P; Vidmar L; Maticic M; Sharma PM; Janez A
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep; 14(3):99-105. PubMed ID: 16200335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.